Financial Reports, Partnerships, Settlement Agreements, and Strategic Acquisitions - Research Report on Mallinckrodt, WellCare, Mindray, Oxygen Biotherapeutics, and Novavax

NEW YORK, November 19, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Mallinckrodt plc (NYSE: MNK), WellCare Health Plans, Inc. (NYSE: WCG), Mindray Medical International Limited (NYSE: MR), Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), and Novavax, Inc. (NASDAQ: NVAX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Mallinckrodt plc Research Report

On November 7, 2013, Mallinckrodt plc (Mallinckrodt) released its Q4 FY 2013 and full-year FY 2013 results (period ended September 27, 2013). Mallinckrodt registered net sales of $552.2 million, up 7.6% YoY in Q4 FY 2013, and net sales of $2.2 billion, also up 7.6% YoY in full-year FY 2013. The Company posted net income of $35.8 million, or $0.62 per share in Q4 FY 2013, compared with 26.2 million, or $0.45 per share in Q4 FY 2012. For full year FY 2013, net income came in at $61.1 million or $1.06 per share, down from $134.6 million or $2.33 per share in full-year FY 2012. Commenting on the results, Mark Trudeau, President and CEO of Mallinckrodt, said, "Our Specialty Pharmaceuticals segment posted strong increases in net sales and operating income, benefiting from higher-margin products in our Brands and Generics portfolios. Looking forward, we are optimistic that successful development of our pipeline will result in launching important new drugs in the market, further driving Specialty Pharmaceuticals segment growth over the long term. We are also fully committed to increasing profitability through company-wide operating efficiencies and growth plans that include targeted international markets." The Full Research Report on Mallinckrodt plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/24f6_MNK

--

WellCare Health Plans, Inc. Research Report

On November 14, 2013, WellCare Health Plans, Inc. (WellCare) reported that the Company supported the American Diabetes Association's Step Out: Walk to Stop Diabetes event in Atlanta on November 9, 2013, to raise awareness and funds to help the nearly 26 million people across the country that are living with the disease. Rená B. Cozart, Executive Director, American Diabetes Association, commented, "The American Diabetes Association, Atlanta/North Georgia Region, is grateful to WellCare for raising awareness through its participation in Atlanta's Step Out: Walk to Stop Diabetes and its sponsorship of Team Red." The Full Research Report on WellCare Health Plans, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/be48_WCG

--

Mindray Medical International Limited Research Report

On November 12, 2013, Mindray Medical International Limited (Mindray) announced a settlement agreement with Beckman Coulter Inc. Mindray reported that Shenzhen Mindray Bio-Medical Electronics Co., Ltd., a subsidiary of Mindray, entered into a settlement agreement related to an ordinary course commercial dispute with an OEM manufacturing customer, Beckman Coulter Inc. on November 11, 2013. The Company informed that in connection with this settlement, it will take a litigation related charge of approximately $15 million in Q4 2013. According to the Company, the commercial dispute did not involve intellectual property or product liability matters, and Mindray has determined that the related termination of the OEM arrangement is not material to its business or operations. The Full Research Report on Mindray Medical International Limited - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/8d4d_MR

--

Oxygen Biotherapeutics, Inc. Research Report

On November 14, 2013, Oxygen Biotherapeutics, Inc. (Oxygen Biotherapeutics) announced that it has closed the acquisition of certain assets of Phyxius Pharma, a privately-held biopharmaceutical company focused on the development and near-term commercialization of levosimendan. Pursuant to the purchase agreement, Oxygen Biotherapeutics reported that it has acquired the exclusive rights to develop and commercialize levosimendan in North America, and will welcome three key Phyxius Pharma executives into its management team. The Full Research Report on Oxygen Biotherapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/5700_OXBT

--

Novavax, Inc. Research Report

On November 12, 2013, Novavax, Inc. (Novavax) released its Q3 2013 results. Novavax registered total revenues of $4.8 million in Q3 2013, down 16.7% YoY. The Company posted net loss of $15.3 million in Q3 2013, compared to net loss of $7.2 million in Q3 2012. Also, Novavax reported diluted loss per share of $0.09 in Q3 2013, compared to diluted loss per share of $0.05 in Q3 2012. The Full Research Report on Novavax, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/bc35_NVAX

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED